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An evaluation of Fracture Liaison Services in the detection and 
management of osteoporotic fragility fractures: a narrative review 
 
Introduction 
Osteoporosis is a bone disease characterised by a loss of bone density and deterioration in 
bone structure. For patients with osteoporosis, the resilience of the bone is compromised, 
placing the patient at an increased risk of a fragility fracture. Osteoporosis is often referred 
to as a ‘silent disease’, where the patient is often asymptomatic until a fracture occurs.  
Fragility fractures are defined as those which occur from low-impact mechanical forces that 
would not normally result in fracture; these are due to low bone density and structural 
deterioration of bone tissue. The World Health Organisation (WHO) has quantified these 
forces as being equivalent to those experienced from a fall from standing height or less.1 
This type of injury can have a very poor prognosis, with fragility fractures of the hip and spine 
associated with increased 5-year mortality rate. A recent study has revealed that 24% of 
women and 20% of men re-fractured, and 26% of women and 37% of men died without re-
fracture in this 5-year period. Of those who re-fractured, a further 50% of women and 75% of 
men died, resulting in a total 5-year mortality rate of 39% in women and 51% in men.2 An 
added complication is that approximately 50% of people with a fragility fracture will suffer 
another. Warning signs do exist for this patient group, as almost half of those that present 
with a hip fracture will have suffered a previous fragility fracture,3 thus highlighting the 
missed opportunities to identify and treat this population. 
This paper presents a synthesis of the current evidence base for the detection and 
management of osteoporotic fragility fractures, including Fracture Liaison Service initiatives. 
A systematic approach was undertaken to identify relevant sources, charting the key findings 
to generate an integrative narrative review and highlighting implications for future 
commissioning and service delivery. 
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An ageing population, a cost to society 
Large increases in life expectancy are being observed in the majority of developed countries. 
As a consequence, the number of fractures in the elderly population is expected to increase.4 
In Australia it is expected that 66% of those aged over 50 will be affected by osteoporosis.5This 
is similar to the UK, where osteoporosis and the associated consequences are becoming ever 
more prevalent, with 1 in 2 women and 1 in 5 men expected to have a fragility fracture after 
the age of 50.1 The synergy of population ageing and osteoporosis will become an economic 
burden.6,7 The human cost is more difficult to measure, but the co-morbidities and potential 
mortality rate associated with an ageing population are not difficult to appreciate. With this 
in mind, it is crucial that secondary prevention becomes a core characteristic in the 
management of fractures and osteoporosis.8 
Cost is always at the forefront of discussion of service delivery and provision in the UK 
National Health Service (NHS), and this is no different in the care of osteoporosis and 
fragility fractures. Osteoporotic fragility fractures are costly both in human and economic 
terms. Over 300,000 patients present with fragility fractures to hospitals in the UK each 
year. Social and medical costs from fragility fractures to the UK healthcare economy were 
estimated at £1.8 billion in 2000, with much of this due to fractures of the hip.8 Due to an 
aging population this has the potential to increase to £2.2 billion by 2025, with most of 
these costs relating to the ongoing care of fragility fractures to the hip, spine, and wrist.9 Hip 
fractures are the most significant type of fragility fracture because of the human impact and 
the need for long-term institutional care, and associated high medical costs.10 The expected 
level of cost is not unique to the UK, where the cost of osteoporosis and fracture care in 
Australia is expected to rise to 3.84 billion Australian Dollars (£2.2 billion) by 2020.5 
Nakayama et al7 paint a similarly bleak worldwide picture in terms of a projected cost of 37 
billion Euros in Europe by 2025 and 12.5 billion US Dollars in China by 2020. Despite these 
large costs, the rate of investigation and treatment of osteoporosis remains low. However, a 
recent technology appraisal of bisphosphonate treatment for osteoporosis by the National 
Institute for Health and Care Excellence (NICE)11 aimed to establish at what level of absolute 
fracture risk the treatments are cost effective. A reduction in price means that 
bisphosphonates are now cost effective even in patients with a low level absolute risk (i.e. 
oral medication should be considered for those with >1% risk of fracture in a 10-year 
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period). The treatment regime should be based on individuals (rather than populations) in 
order to understand relative advantages and disadvantages. For those patients considered 
higher risk (>10% risk of fracture in a 10-year period), or those who cannot tolerate oral 
medications, it is appropriate to offer intravenous bisphosphonates. This new cost 
assessment should encourage the use of bisphosphonate treatment in patients who are at 
risk of fragility fracture. 
 
Fragility fracture identification: the role of radiology 
Positive identification of fragility fractures is critical to the care of patients with osteoporosis. 
Vertebral fractures are the most common type of fragility fracture, accounting for almost half 
of all fractures due to osteoporosis.12,13 They are a significant health concern due to the 
increased risk of future fractures and an associated increase in morbidity and mortality.14,15 
In this patient group, a previous fracture is thought to double the risk for subsequent 
fractures, and in the case of vertebral fractures this risk is quadrupled.4 The risk of vertebral 
fracture increases exponentially with a greater number of prior vertebral fractures; known as 
the vertebral fracture cascade. As a further complication the risk of hip fracture is also 
doubled.13,16 
Despite the clinical significance of vertebral fractures, these are often overlooked clinically 
and/or radiologically, with many studies demonstrating that the under-reporting of vertebral 
fractures is a world-wide problem.14,16–18 In Europe, around 1/3rd of vertebral fractures are 
overlooked and this has been attributed to asymptomatic presentation, lack of radiographic 
detection and ambiguous terminology in the radiological report (i.e. wedging, vertebral 
height loss, deformity, or end-plate infraction or depression).13,14 Even when they are 
detected in hospital, it does not necessarily mean that it will lead on to an assessment of bone 
health or subsequent treatment.15 
In the clinical setting the asymptomatic nature of vertebral fractures presents a challenge, 
meaning that they can go untreated and the future fracture risk remains. So how can 
radiology help? 
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The National Osteoporosis Society (NOS) has provided recent guidance19 about the detection 
of vertebral fractures, where it explains the critical role of diagnostic imaging services. 
Radiology practitioners are often best placed to initiate the most substantial improvements 
in the vertebral fracture pathway – starting with effective detection of fractures. The NOS has 
recommended that local protocols are established to ensure that the spine is routinely 
evaluated for the presence of vertebral fractures of the thoracic and lumbar spine on any 
imaging, regardless of the clinical question. Upon identification of a fracture the referring 
clinician should be alerted, using a fail-safe mechanism, so that they understand need to 
investigate the patient for fracture risk. It is crucial that unambiguous terminology is used and 
the NOS has recommended that the condition of the vertebral body should be clearly 
described in one of three ways: (i) vertebral fracture (including level, severity and timing), (ii) 
non-fracture vertebral deformity (i.e. Scheuermann’s disease or Schmorl’s nodes), and (iii) 
normal.19 The NOS also provide suggested standard phrases that could be used in a 
radiological report. 
In addition to the targeted identification proposed by the National Osteoporosis Society, 
reporting practitioners should always be aware of the opportunistic chance to identify 
fragility fractures. Incidental diagnosis of fragility fractures can often be made on computed 
tomography (CT) scans of the thorax and abdomen. Multi-Detector CT (MCDT) midline sagittal 
images can routinely be reformatted (without additional radiation dose to the patient) to help 
identify fragility fractures. Sagittal reformats are particularly sensitive for identification of 
vertebral fractures due to good visualisation of the middle of the end plate, where 
insufficiency fractures typically occur.16,20 
Although the clinical significance of vertebral fractures is understood and the importance of 
opportunistically identifying such fractures has been recognised, there is still significant 
under-reporting. Widespread underreporting occurs in all imaging techniques, with MDCT 
missing more opportunities than radiographic imaging.16 Standardisation of the radiological 
assessment of vertebral fractures is also required, where clinicians often fail to recognise or 
report mild to moderate vertebral fractures, or use terminology that is not specific for 
fracture.20 Effective communication to the wider team caring for these patients is critical to 
ensure that eligible patients receive either dual-energy X-ray absorptiometry (DXA) or 
pharmacologic therapy to reduce future fracture risk. 20,21 Correct identification of fragility 
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fractures that leads onto suitable investigation is the key improvement required for 
secondary prevention.15 
 
Fracture Liaison Services: a long-term solution, not a quick fix 
To reduce the risk of re-fracture a co-ordinated approach is needed to identify patients most 
at risk. A Fracture Liaison Service (FLS) is a proven approach to delivering comprehensive 
secondary prevention, which requires a multidisciplinary approach to be an effective service. 
This should comprise osteoporosis assessment and treatment together with a falls risk 
assessment. Ideally this would occur in a streamlined ‘one-stop shop’ setting. However, the 
challenge of organising such services and integrating them across acute and primary care is 
considerable.22 A raised awareness of such services must be a priority. 
Cost appears to be a significant factor affecting the development of FLS within the NHS, but 
it is the longer-term cost-saving and patient benefit that needs to be considered. The financial 
value of FLS is based on reducing fragility fractures in a population. In 2009 the Department 
of Health provided an economic evaluation of fracture prevention services, where it was 
suggested that £8.5 million could be saved nationally over a 5 year period.23 Despite this, such 
services are not universally adopted and this may in part be due to more modest estimations 
of cost saving.24 There is some evidence that a FLS can be effective when comparing small 
cohorts of patients that are treated against those that are not, but demonstrating financial 
value in an entire population is a challenge. It is suggested that demonstrating value of a FLS 
at a statistically significant level is impossible in a 1-3 year period, over which the financial 
value of a service is typically evaluated.25 Furthermore it has also been implied that current 
commissioning and budgeting processes within the NHS do not incentivise this type of service: 
when Sutcliff8 made this suggestion in 2008 a FLS was available in only 30% of NHS institutes. 
Nevertheless, investing in FLS should ultimately lead to lower overall healthcare costs, though 
the cost-effectiveness of each FLS is dependent on the structure, context, and geographical 
nature of the service.15 It is therefore important to establish what constitutes an effective FLS 
model of care. UK national clinical standards for FLS have been published by the National 
Osteoporosis Society (NOS) 5IQ model.25 
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Other models of care have been suggested, and will be considered later in this paper, but a 
FLS is recognised as the current model of best practice.8 The main purpose of a FLS is to 
correctly identify patients with fragility fractures and subsequently provide them with 
appropriate follow-on treatment and assessment of bone health and future fracture risk.7,15 
For all patients the aim is to extend care beyond healing of the first fracture and aim to reduce 
the risk of subsequent fractures, in particular those that are associated with higher morbidity 
(i.e. hip, vertebral).8,15  
The British Orthopaedic Association set out six standards for hip fracture care. Standard 5 
states that all patients presenting with fragility fracture should be assessed to determine their 
need for anti-resorptive therapy to prevent future osteoporotic fractures.22 A FLS should be 
applied to all patients of ≥50 years and older who present with fragility fractures8,22 and it 
should also target patients with a previous history of fracture. This targeted treatment via 
implementation of a FLS is associated with better diagnosis of osteoporosis and a reduction 
in the number of secondary fractures.5 
A FLS based within an acute setting serves to improve care for patients who present with a 
low impact (fragility) fracture i.e. gained from a fall, slip or trip. Patients should receive a 
clinical assessment by a specialist FLS coordinator or specialist nurse, and some patients will 
also undergo DXA bone density measurements at the spine and hip (in accordance with NICE 
guidance TA161). Treatment for osteoporosis is typically recommended in about 75% of these 
cases.23 There is an now an acceptance that FLS should be the standard of care, and not an 
optional extra.25 
 
A gap in care 
The adoption of FLS is not universal worldwide, or even throughout the NHS. Reduced or 
alternative models have been implemented, with reliance on referral letters being sent to 
primary care physicians in general practice or to endocrinologists. Those systems have been 
found to be less effective than FLS, which leads the way in terms of diagnosis and treatment 
to prevent secondary fracture.26 These less intensive models that focus on improving 
knowledge of bone health have not yielded positive results in terms of re-fracture rate,15 
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while services that are reliant on letters to primary care result in low prescription rates of 
bisphosphonates.25 In addition, community based models suffer through low attendance 
rates (~45%) for follow-on DXA.25 In addition, DXA alone is not sufficient to provide an 
accurate prediction of fracture risk. A range of other non-bone mineral density related risk 
factors are required to accurately estimate the probability of fracture.4,15 Studies from the 
UK suggest that only one third of patients with a fracture undergo osteoporosis risk 
assessment and subsequent treatment for secondary prevention of fracture,22,27 despite the 
fact that it is recommended that a FLS should be available in all hospitals that provide 
definitive fracture care. 
A study by Nakayama et al7 compared the outcomes for patients in hospitals with and 
without a FLS. Those patients treated at a hospital with a FLS were less likely to experience 
major and minor secondary fractures. Walters et al15 also report on a significant reduction in 
secondary fractures over a 2-4 year period when using a FLS compared to primary care 
follow-up or hospitals that did not use FLS. Cases of poor post fracture care have been 
attributed to a lack of leadership by any single profession,26 thus highlighting the need for a 
robust service with competent communication channels. When separate professional 
groups are left to treat the patients independently, instead of following a proper model, the 
overall care can suffer despite the best efforts of those involved. Mitchell et al28 report that 
while orthopaedic surgeons are capable of delivering expert care for acute injury, they may 
not be the best at initiating the appropriate follow-up to investigate and treat the primary 
cause (i.e. osteoporosis). The same is true in primary care where the general practitioners 
may not instigate treatment unless it is recommended in a discharge summary by a 
specialist practitioner. Furthermore, a hospital based specialist may also not deliver the best 
care if their actions are not captured by a robust system supported by other professional 
groups, as would be found in a FLS. There are also reports of misrepresentation of DXA 
results, where multiple findings from the same examination are not successfully recorded  
due to a lack of compatibility of computer programs in the primary care setting.29 
This is not to say that all FLS are infallible, as was found in an Australian study. Although 
compliance with national standards related to osteoporosis were improved alongside 
patient satisfaction, only 61% of patients went on to receive therapy that was specific to 
osteoporosis. This was thought to be because the presentation of fracture was not always 
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typical, the degree of trauma appeared consistent with injury, or the patient refused 
treatment. On a positive note, based on their data it was predicted that secondary fractures 
would reduce by 16%.5 
Orthogeriatric services (OGS) often run alongside a FLS in order to help with the care of elderly 
patients who are admitted to hospital following fracture. These patients are often too frail to 
attend outpatient appointments and OGS is valuable for the secondary prevention of 
fractures in these cases.30 High-quality and standardized care requires the development of 
specific local protocols based on national guidelines, to ensure clear directives on the delivery 
of post fragility fracture care. There is an ongoing debate among service leaders about the 
best way to organize and deliver a FLS. Currently, many primary care providers and acute 
trusts lack a systematic, case-finding approach to identify and treat osteoporosis in high-risk 
groups (i.e. post-menopausal women who have sustained a fragility fracture).  
The introduction of secondary prevention of fragility fractures within the NHS Quality and 
Outcomes Framework (QOF) intends to incentivise the implementation of services in 
therapeutic domains, such as the care of fragility fractures.28 The QOF initiative is aimed at 
improving the standards in primary care by focusing on the results achieved in general 
practice. It rewards  management of chronic conditions, major public health concerns and the 
implementation of preventative measures; so it is not difficult to appreciate how the care of 
fragility fractures and those with osteoporosis can fit this model. The NICE QOF indicators for 
this area are NM29, NM30 and NM31.31 These are based on accurate record keeping of 
patients who have a confirmed diagnosed of osteoporosis and have sustained a fragility 
fracture (NM29), and those with fragility fractures who are currently being treated with bone 
sparing agents (NM30/NM31). The categories are dependent on age, the timing of the 
fracture, and whether the diagnosis was made using DXA.31 The ‘point’ scoring model 
employed by QOF suggests a small improvement for the management of patients with 
osteoporosis from 2015/16 to 2016/17 but it may be too early to state this as a success. QOF 
has prompted improvements in care in the early years following implementation, but there 
is a persistant worry that once the pay for performance incentive expires, the quality of care 
may decline.32 In addition, there is no clear evidence to suggest that this improves patient 
outcomes,33 or that it is cost-effective compared to other methods of improving care.34 
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Conclusion 
The financial value of FLS is based on reducing fragility fractures and the investment should 
reduce the cost of ongoing care in a population. However, the initial cost of implementation 
appears to be a significant factor affecting the adoption of FLS within the NHS despite the 
service being associated with better diagnosis of osteoporosis and a reduction in the number 
of secondary fractures. 
Radiology has a key role to play in the positive identification of fragility fractures to ensure 
optimal, patient-centric care. To improve case finding of vertebral fractures, diagnostic 
imaging departments must follow fail-safe mechanisms and reporting guidelines to ensure all 
patients with fragility fracture are captured and cared for. The reduced cost of 
bisphosphonate treatment may potentially help to achieve longer term reductions in fragility 
fractures. 
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